The VCRC Clinical Outcomes Program leverages the network of VCRC sites with expertise in the clinical care of patients with vasculitis to conduct high-quality clinical outcomes research in rare diseases. Patients with different forms of vasculitis are comprehensively phenotyped at multiple time points in the disease course in both observational and clinical trial settings. The long-term goal of the VCRC Clinical Data Outcomes Program is to improve clinical outcomes of patients with all types of vasculitis through improved understanding of the natural history, epidemiology, and efficacy of therapeutic interventions. The objective of the program is to study clinical outcomes in parallel across seven primary types of vasculitis. The rationale to the approach is that multi-center research in rare diseases using standardized data collection practices is an efficient and effective method to conduct high-quality clinical outcomes research in rare diseases.
The specific aims of this project are: 1. Maintain the infrastructure that supplies, stores and utilizes all clinical data collected in the VCRC Longitudinal Studies and clinical trials within the VCRC Clinical Data Repository for clinical outcomes research in vasculitis; 2. Conduct meaningful clinical outcomes research in vasculitis using prospectively-collected data in the following areas: natural history studies, clinical outcome studies, and outcome measure assessments. 3. Facilitate interaction among VCRC members focused on the use of clinical data that promotes the training of young investigators and the development of novel analytic approaches to rare disease research. By leveraging existing infrastructure within the VCRC, including the VCRC Longitudinal Studies, VCRC-led clinical trials, the VCRC Clinical Data Repository, and the expertise of the VCRC Steering Committee, the VCRC Clinical Data Outcomes Program overcomes challenges common to rare disease research. The collaborative effort required of the VCRC centers to complete initiatives within the VCRC Clinical Outcomes Program serves as a template for conducting research in rare diseases.

Public Health Relevance

The VCRC Clinical Outcomes Program leverages the network of VCRC sites with expertise in the clinical care of patients with vasculitis to conduct high-quality clinical outcomes research in rare diseases. The longterm goal ofthe VCRC Clinical Data Outcomes Program is to improve clinical outcomes of patients with all types of vasculitis through improved understanding of the natural history, epidemiology, and efficacy of therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54AR057319-12
Application #
8909286
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Wang, Yan Z
Project Start
2014-09-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$114,119
Indirect Cost
$9,347
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066
Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 69:846-853
Milman, N; Boonen, A; Tugwell, P et al. (2017) Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. Scand J Rheumatol 46:112-117
Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69:837-845
Carmona, F David; Coit, Patrick; Saruhan-Direskeneli, G├╝her et al. (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953
Selewski, David T; Thompson, Aliza; Kovacs, Sarrit et al. (2017) Patient-Reported Outcomes in Glomerular Disease. Clin J Am Soc Nephrol 12:140-148
Oommen, Esha; Hummel, Amber; Allmannsberger, Lisa et al. (2017) IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clin Exp Rheumatol 35 Suppl 103:98-101
Gopaluni, Seerapani; Smith, Rona M; Lewin, Michelle et al. (2017) Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials 18:112
Carmona, F David; Vaglio, Augusto; Mackie, Sarah L et al. (2017) A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet 100:64-74
Sreih, Antoine G; Alibaz-Oner, Fatma; Kermani, Tanaz A et al. (2017) Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. J Rheumatol 44:1933-1937

Showing the most recent 10 out of 72 publications